Sequana Medical is a commercial stage medical device company and an innovator in the management of liver disease. The first product, alfapump®, is a fully implantable, programmable, transcutaneously-charged, battery-powered pump for the management of refractory ascites (chronic fluid build-up in the abdomen).
The alfapump® is a fully implanted, automatic battery-operated pump, charged through the skin, that automaticallly and continually moves ascites from the abdominal cavity to the bladder, where it is excreted naturally from the body for improved patient’s quality of life
Through the experience from the design, development, manufacture and commercialisation of the alfapump®, together with the extensive intellectual property portfolio, Sequana Medical is developing an enabling platform for the management of heart failure and other fluid-imbalance disorders
The first prototypes were built in 2005 and the founders demonstrated the technical feasibility of the approach. First patients were implanted in 2008 and in 2011 the company received the CE-mark for removal of cirrhotic ascites following completion of the PIONEER clinical study. The alfapump was commercially launched at EASL in 2012 and in the same year the CE-mark was received for removal of malignant ascites.
Since then Sequana Medical has continued to invest in the clinical, technical and commercial development of the alfapump®. This includes the completion of the MOSAIC IDE study in North America and the publication of the results of the European randomised controlled trial and the Post-Marketing Surveillance Registry.
Chief Executive Officer
Ian has over 25 years of experience in the healthcare sector, both in-house at medical device and pharmaceutical companies, and as an investment banker at leading global firms. He has extensive expertise and a strong track record in capital markets, licensing and strategic transactions. Prior to joining Sequana Medical, Ian was Chief Financial Officer of GC Aesthetics Ltd. based in Dublin.
Before that, Mr. Crosbie was Senior Vice President, Corporate Development at Circassia Pharmaceuticals plc, a late-stage biopharmaceutical company focused on allergy immunotherapy where he led the execution of the company’s ₤210 million IPO, as well as the M&A & licensing activities. Prior to Circassia, Ian enjoyed a 20-year career in corporate finance, including Managing Director, Healthcare Investment Banking at Jefferies International Limited and Director, Healthcare Investment Banking at Deutsche Bank. He has a degree in Engineering, Economics and Management from Oxford University.
Chief Financial Officer
Kirsten is a seasoned finance executive with over 20 years of international experience in the healthcare industry. Prior to joining Sequana Medical, Kirsten was Vice President of Finance at Fagron, North America, where she was responsible for creating and overseeing the company’s financial strategy and policy and positioning Fagron’s North American companies for growth.
Before that, Kirsten served as Chief Financial Officer for Arseus Dental & Medical Solutions, where she was instrumental in the coordination, support and control of financial activities in key European countries. Her previous roles include Financial Controller at Omega Pharma and Audit Manager at PwC. Kirsten has a degree in Financial and Fiscal Sciences from the University of Antwerp, Belgium.
MD, Consulting Chief Medical Officer
Gijs has over 14 years academic and health care industry experience. After his training in abdominal surgery at the University of Leuven, he held multiple positions in Medical Affairs, Clinical and Marketing at large pharmaceutical (Sanofi, AstraZeneca) and medical device companies. These include roles as Director of Medical Affairs Europe at Boston Scientific, providing leadership to the medical support for the portfolio of products in the Structural Heart and Medical / Surgical divisions, and as Worldwide Medical Director Clinical Research at Johnson & Johnson’s medical device division (Cordis and Cardiovascular Care Franchise), supporting the clinical development of different products through regulatory submission (CE mark & IDE), post-market commitments and development. Most recently, he is a consultant specialized in clinical and medical support for medical device companies. Gijs holds an MD from the University of Leuven and a degree in Business Administration from the Institute for Pharmaceutical Business Administration (IFB).
Global Vice President QM/QA/RA
Orlando has over 17 years of experience within quality management, quality assurance, clinical and regulatory affairs in the medical device industry. Antunes graduated as a mechanical engineer in 1993 and began his professional career in the R&D team of PLUS Orthopedics AG, a Swiss orthopedics manufacturer, and in 1998 assumed global responsibility for the Regulatory Affairs department.
Since then he has served as Head of QM/RA at Thommen Medical AG, Head of QM/RA at Philips AG in Zurich, with specific responsibility for the ALPS Healthcare division, as well as Vice President of RA at Medela AG. Orlando chairs the mirror groups of ISO TC 210 and CEN TC 03 at the Swiss Standards Association and is the official Swiss Representative for these technical committees at ISO- and CEN-Level. He is also a long term member of various working groups related to regulatory activities at EUCOMED, the European Confederation of Medical Devices Manufacturers in Brussels.
Orlando holds a dual degree Master in Business Administration from the University of Bern and Rochester, NY in the USA.
Global Vice President Engineering and Manufacturing
Dirk has over 15 years’ experience in research and development in multidisciplinary high-tech environments. He has extensive expertise in developing innovative solutions for the medical device industry. Prior to joining Sequana Medical, Dirk lead the Sensors Systems group at the Swiss Center for Electronics and Microtechnology (CSEM) for 10 years, where his team specialized in developing innovative sensors, mechatronic systems and automated fluid handling solutions to create unique selling propositions on behalf of various industry partners.
In his role, Dirk was also responsible for aligning the research strategy in the automation field with industry needs and he mentored research and industry projects.
Prior to CSEM, he was responsible for the development of next generation products in two medical start-up companies, one in Switzerland and one in Silicon Valley, where both products reached market maturity. Dirk holds a Masters in Electrical Engineering from the Swiss Federal Institute of Technology, Zürich (ETH).
Chief Commercial Officer
Martijn has over 15 years’ experience in the life sciences industry. Most recently he was the Director of International Marketing at Myriad Genetics, responsible for the marketing development of genetic testing in the international markets.
Previous to Myriad, he worked as Director of Marketing and Market Development at PulmonX, a start up from Redwood City focusing on developing and marketing minimally-invasive medical devices and technologies to expand and improve treatment options for emphysema patients.
Prior to this he was Director International Marketing with Alere where he spent more than 7 years leading the marketing, training and marketing communications teams, for all of their business units: Cardiology, Women’s Health, Oncology, Infectious Diseases, Blood Borne Pathogens, Toxicology and Health Management. Martijn studied economics at the MEAO in Breda and specialized at de Rooi Pannen in Marketing and Sales management.
He is managing partner of the LSP Health Economics Fund, a fund investing in medical device, diagnostic and digital health companies. Rudy currently serves on the Board of Directors of Sequana Medical, Curetis, reMYND, Celyad and EMBLEM and has served on many other biotech boards such as Devgen, CropDesign, Ablynx, Actogenix and Multiplicom. Prior to joining LSP, he was one of the co-founders of VIB and co-managing director of this research institute for 17 years, during which he was also responsible for the business development. Under his leadership VIB has built a patent portfolio exceeding 200 patent families, signed 800 R&D and license agreements, spun out twelve companies and laid the foundation for bio-incubators, bio-accelerators and the biotech association FlandersBio. Rudy holds a Ph.D in molecular biology from the University of Ghent where he was also professor innovation management till 2012.
He is the chairman and founder of NeoMed Management in 1997. Prior to that, he has been Chairman and controlling shareholder of NeoMed AS, providing investment advisory services, specializing in small and medium sized companies in the pharmaceutical, medical device and diagnostic industries. From 1993 to 1997, NeoMed AS co-managed two private equity investment companies, KS Nordic Healthcare Partners and Viking Medical Ventures Limited. He has served as a board member of Clavis Pharma AS, GenoVision AS/Qiagen AS, Thommen Medical AG, Vessix Vascular Inc. and Sonendo Inc., and currently serves on the Board of Directors of JenaValve Technology Inc. and CorFlow Therapeutics AG. He is a founder and former Chairman of the Norwegian Venture Capital Association. He holds a Dr. scient. degree in organic chemistry from the University of Oslo and a Master of Science degree in Management from the Graduate School of Business, Stanford University, USA. He is a Swiss citizen.
Global Vice President QM/QA/RA
Has over 20 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry as General Partner for VI Partners, he has held various managerial positions in the pharmaceuticals and medical devices sectors. In addition to his role in Sequana Medical , Diego presently represents VI Partners in various biotech start-ups companies.
Diego holds a M.Sc. in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne.
NeoMed Management is a Jersey headquartered investment firm, exclusively focused on investments in the healthcare industry. Founded in 1997, NeoMed has established six funds to date.
NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that address substantial market opportunities in the pharmaceutical, medical device and diagnostics industries.
NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 40 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.
From offices in Jersey, Switzerland and Norway, NeoMed’s experienced investment team works closely with entrepreneurs and a broader industry network to support the growth of its portfolio companies.
VI Partners is a Swiss venture capital firm that supports university spin-offs as well as other promising start-up companies with capital, coaching, consulting and networks. Venture Incubator was established by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ), and started operations in 2001. Currently, VI Partners holds investments in more than 30 companies. Via the “Venture Incubator” fund VI Partners invests “Smart Money” to develop promising technology-based ideas for products and services into successful businesses. It now manages an investment fund of CHF 101 million. VI Partners investors represent 10 blue-chip enterprises from industry and finance.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. The BioMedInvest vehicle targets the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology. Based in Basel, BioMedPartners has successfully invested in more than 35 human life science companies over the last ten years, of which a large number have already been listed on the stock exchange or have been acquired by leading players in the pharmaceutical industry.
Capricorn Venture Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as competitive advantage. It is based in Leuven, Belgium and licensed by the Financial Services and Markets Authority in Belgium.
The Entrepreneurs Fund provides early stage and growth financing alongside active support to entrepreneurial teams. The Entrepreneurs Fund brings the long term perspective, experience and global outlook of a family business in its 5th generation. It is their ambition to create relationships that are valuable and valued. And to actively contribute more to those relationships. The Entrepreneurs Fund is the venture capital member of the COFRA Group.
LSP is one of Europe’s leading investors in the health care sector. Over more than 25 years, LSP has built elaborate expertise in establishing and growing health care companies with a positive impact on society. In partnership with inventors and entrepreneurs LSP contributes to the translation of breakthrough concepts into products that benefit patients. LSP connects LPs to inventors with a dual goal: generating an interesting financial return and contributing to the quality of life. LSP’s Health Economics Fund invests in innovative products contributing to a better and cheaper health care.
Salus Partners is a Swiss investment and advisory firm that supports the development of the most promising health technology companies with potential to make a global impact in healthcare. Salus Partners offers truly independent investment advice with knowledge and access in the financial and healthcare sectors in partnership with the most promising entrepreneurs and investment managers who seek to generate sustainable financial returns while bringing good outcomes to society.
QUEST FOR GROWTH, Privak (closed-end private equity fund), a closed-end undertaking for collective investment (UCI) under Belgian law. The diversified portfolio of Quest for Growth chiefly comprises investments in growth undertakings listed at European stock exchanges, European unlisted companies and venture capital funds. Quest for Growth focuses on innovative companies in areas such as information and communication technology (ICT), technologies for the healthcare sector (Health-tech) and clean technology (Cleantech). Quest for Growth has been listed on Euronext Brussels since 23 September 1998.